Ranking high blood pressure drug combinations from most to least tolerated

The Global Hypertension Report by the World Health Organization (WHO) revealed that 1.4 billion people were living with ...
Medscape

Baxdrostat Approval May Open New Doors for Personalized Hypertension Treatment

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy

AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

Controlled Blood Pressure Isn’t A Cure: Doctor Warns About Hypertension Myths

Doctors warn that hypertension is rising rapidly among younger Indians, while myths about symptoms, salt, and medication ...
Monthly Prescribing Reference

Baxfendy Earns FDA Nod as First-in-Class Hypertension Treatment

Credit: AstraZeneca. Baxfendy offers novel mechanism of action for patients whose blood pressure remains uncontrolled despite background antihypertensive therapy. According to AstraZeneca, Baxfendy is ...

Hypertension causes silent damage if treatment is ignored: Experts

Panaji: As hypertension doesn’t often produce any symptoms, many tend to ignore regular blood pressure (BP) checks, unaware ...
Medscape

Is Hypertension Undertreated in Pediatrics?

Pediatric hypertension is a significant concern because it can persist into adulthood and contribute to cardiovascular ...
The Manila Times

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and ...
Healio

Even with HCV cure, surveillance for portal hypertension, HCC ‘should be mandatory’

Please provide your email address to receive an email when new articles are posted on . Sustained virologic response occurred in 81.8% of patients after the first DAA treatment course. Despite this, ...